The Process of Seeking Psychotherapy and Its Impact on Therapy Expectations and Experiences

2014 ◽  
Vol 22 (5) ◽  
pp. 399-408 ◽  
Author(s):  
Katherine P. Elliott ◽  
Robin Westmacott ◽  
John Hunsley ◽  
Orly Rumstein-McKean ◽  
Marlene Best
Keyword(s):  
Therapy Expectations

Predictive Factors in the Treatment of Obsessive-Compulsive Disorders with Fluvoxamine and/or Behaviour Therapy

1993 ◽  
Vol 21 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Jean Cottraux ◽  
Philippe Messy ◽  
Isaac M. Marks ◽  
Evelyne Mollard ◽  
Martine Bouvard
Keyword(s):  
Rating Scale ◽  
Group Versus ◽  
Controlled Study ◽  
Stepwise Discriminant Analysis ◽  
Behaviour Therapy ◽  
Obsessive Compulsive ◽  
Avoidance Score ◽  
Obsessive Compulsive Disorders ◽  
Therapy Expectations ◽  
Compulsive Disorders

Fisher's stepwise discriminant analysis was carried out on 10 baseline variables searching for posterior prediction of success in a sample of sixty DSM-III obsessive-compulsive patients. The patients' median score on Hamilton rating scale of depression was 19. In a controlled study they were randomized into three groups: fluvoxamine with antiexposure, fluvoxamine with exposure, or placebo with exposure. In the whole sample, five variables accounted for 76% of the correctly classified patients: avoidance score of the behavioural avoidance test, behaviour therapy expectations, fluvoxamine expectations, Beck depression inventory and rituals repetition. High avoidance score predicted 68% of the correctly classified patients in the whole sample. The discriminant function classified correctly 70% of the patients in the antiexposure with fluvoxamine group, versus 75% in the exposure with fluvoxamine group, and 85% of the patients receiving exposure with placebo (χ2, d.f.2, NS).

Advances in male and female sex therapy: Expectations and disappointments

2011 ◽  
Vol 26 (S2) ◽  
pp. 2036-2036
Author(s):  
Z. Zemishlany
Keyword(s):  
Sex Therapy ◽  
Pharmacological Agents ◽  
Low Sexual Desire ◽  
Key Issues ◽  
Duration Relationship ◽  
Therapy Expectations ◽  
Serotonin 2A ◽  
Male Erectile Dysfunction

The introduction of the PDE-5 inhibitors for male erectile dysfunction (ED) evolved expectations for 70–80% of efficacy as has been shown in short term studies. Ten years later, we are aware of their limitation: PDE-5 inhibitors are not efficient when desire is lacking, as well as in severe ED. Also, long term studies showed a lesser degree of efficacy.The new pharmacological treatment for premature ejaculation, Dapoxetine, has been developed as a short acting SSRI. It has been shown to increase the time for ejaculation by three folds but has some adverse effects including nausea and fainting (due to hypotension).Low desire is the most common sexual complaint in females. New pharmacological treatments include Bupropion 150 mg/day and Flibanserin 150 mg/day, although the evidence for efficacy is not conclusive. Their proposed mechanism is an increase in dopamine and norepinephrine activity. Flibanserin is an antagonist at the serotonin 2A receptor and an agonist of the serotonin 1A and dopamine D4 receptors.Estrogen and/or testosterone replacement may be beneficial in appropriate cases.There is a growing awareness in the last decade that low sexual desire in women is associated with age, relationship duration, relationship distress and complaints of anxiety and depression. Those psycho-social factors might limit the role of pharmacological agents.Sex therapy should always consider and relate to these key issues

Sign in / Sign up

Export Citation Format

Share Document